What Green Cross Lab Cell does

GC Cell Corporation (KOSDAQ: 144510) is a South Korea-based, fully integrated cell and gene therapy company operating across four business lines: commercial cell therapy (anchored by Immuncell-LC, the world's only approved autologous CIK T cell therapy for hepatocellular carcinoma adjuvant treatment, with over 10,000 patients treated since 2007 MFDS approval), end-to-end CDMO services for autologous and allogeneic NK/CAR-NK/CAR-T modalities (Asia-scale 20,806 m² facility with 14 clean rooms plus 75,000 sq.ft. of US capacity via Made Scientific), diagnostic specimen testing and bio-logistics through a 5,000+ medical institution network, and subscription cord blood banking. The proprietary technology stack centers on the eHut78 engineered feeder cell system enabling up to 5,000 NK doses per cord blood unit, a CAR platform with CD28/OX40L costimulation and IL-15 armoring, and cryopreservation technology — protected by patents in Korea, Australia, and multiple PCT filings. The pipeline extends Immuncell-LC into pancreatic cancer (Phase 3) and adds gene-engineered allogeneic CAR-NK candidates GCC4001/AB-101, GCC2003/AB-201 (HER2), GCC2004/AB-202 (CD19), and GCC2005/AB-205 (CD5).

The business model blends one-time commercial product sales (Immuncell-LC and 15-year exclusive license revenue such as the PT Bifarma Adiluhung Indonesia deal), project-based CDMO managed services contracts with pharma and biotech clients, subscription cord blood banking (17-40 year storage contracts), and diagnostic/managed-services revenue via GC Labs. Geographic expansion is pursued via licensing and technology transfer agreements in Indonesia, Taiwan, and Europe, while cross-border CDMO delivery leverages APAC and US manufacturing sites. Reported revenue was KRW 157,544 million in 2023 (down from KRW 236,120 million in 2022), and the company operates as a subsidiary of GC Holdings (Green Cross Corporation group), with GC Biopharma holding a 33.28% stake as of December 2022.

Name

Green Cross Lab Cell

Legal name

GC Cell Corporation

Website

https://gccell.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

501–1,000 employees

Short description

GC Cell (Green Cross Lab Cell) is a South Korean integrated cell and gene therapy company that develops and commercializes Immuncell-LC (an FDA orphan-designated, MFDS-approved autologous CIK T cell therapy for hepatocellular carcinoma adjuvant treatment), provides end-to-end cell therapy CDMO services across APAC and US facilities, and operates diagnostic, bio-logistics, and cord blood banking businesses.

Ownership category

akta.pro rank

Product category

Cell and Gene Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Medical Laboratories (621511), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA)

Keywords

• Cell therapy products
• Cell therapy CDMO
• Cord blood banking
• Cold chain logistics
• Clinical diagnostics services

Headquarters

HQ city

Yongin

HQ country

South Korea

HQ region

Asia

Offices8 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Commercial Cell Therapy Product Sales (Immuncell-LC): GC Cell generates revenue from the commercial sale of Immuncell-LC, its MFDS-approved autologous CIK T cell therapy for hepatocellular carcinoma adjuvant treatment, administered to over 10,000 patients in South Korea. Revenue also flows from international licensing agreements such as the 15-year exclusive license with PT Bifarma Adiluhung for Indonesian commercialization.
2. CDMO Services: GC Cell provides end-to-end contract development and manufacturing organization (CDMO) services for cell and gene therapy products, covering process development, analytical development, clinical and commercial manufacturing, and regulatory consulting. Revenue is generated through project-based contracts with pharma and biotech partners.
3. Cord Blood Banking Services: GC Cell Life Line green cord blood banking service charges customers for collection, processing, cryogenic storage, and genetic testing of cord blood stem cells. Storage contracts are typically long-term (17–40 years).
4. Diagnostic Testing and Bio-Logistics Services: GC Cell provides diagnostic specimen testing services through a network of 5,000+ medical institutions via GC Labs, and bio-logistics cold chain supply services including clinical trial logistics, cell and gene therapy logistics, and commercial product distribution.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

Green Cross Lab Cell develops, manufactures, and commercializes cell therapy products—most notably Immuncell-LC, an autologous CIK cell therapy approved in South Korea for hepatocellular carcinoma—and provides integrated CDMO services for cell and gene therapy developers. Beyond therapeutics, it operates a GMP-accredited cord blood banking service (GC Cell Life Line green), a bio-logistics cold-chain platform for living-cell transport, and clinical diagnostic testing through GC Labs, positioning itself as a one-stop cell therapy solutions provider.

Product overview

GC Cell (Green Cross Lab Cell) is a fully integrated cell and gene therapy company offering a unified portfolio spanning research, development, manufacturing, commercialization, and distribution. The portfolio is anchored by Immuncell-LC, the world's only approved HCC adjuvant cell therapy, complemented by a CDMO division providing end-to-end manufacturing from its APAC and US facilities, a cold-chain bio logistics service (G-HUB, CELL TRACK™, CELL PATH™), a cord blood banking service (GC Cell Life Line green), diagnostic testing through GC Labs, and a clinical laboratory services affiliate (GCCL). The development pipeline extends the platform through allogeneic CAR-NK candidates (GCC4001/AB-101, GCC2003/AB-201, GCC2004/AB-202, GCC2005/AB-205) and expansion of Immuncell-LC into pancreatic cancer (GCC4002 Phase 3). Subsidiaries and affiliates include Artiva Biotherapeutics (US, NK cell therapies), Made Scientific (US CDMO), GC Lymphotec (Japan, LuLym-T), and GCCL (Korea, clinical lab). The company operates under the GC (Green Cross) Holdings group, with its own stock listed on KOSDAQ (Ticker: KQ 144510).

Differentiator

Problem solved

Functional benefit

Brands

• Immuncell-LC: Autologous cytokine-induced killer (CIK) T cell therapy for hepatocellular carcinoma adjuvant treatment; the only approved HCC adjuvant therapy globally; FDA orphan drug designation for liver cancer, brain, and pancreatic cancer.
• GC Cell Life Line green
• CELL TRACK
• CELL PATH
• G-HUB

Products and services

• Immuncell-LC Autologous cytokine-induced killer (CIK) cell therapy indicated for hepatocellular carcinoma, manufactured from a patient's own peripheral blood cells and infused to treat liver cancer.
• Cell Therapy CDMO Services Contract development, manufacturing and analytical services for cell and gene therapy developers, covering process development, GMP manufacturing, and quality/regulatory support.
• GC Cell Life Line green Cord Blood Banking Long-term storage service for umbilical cord blood-derived stem cells collected at birth, processed and stored in a GMP-grade facility, with storage terms of 17 to 40 years.
• Bio Logistics Cold Chain Services Specialized cold-chain logistics service that transports living cells, stem cells and biological samples under validated cryogenic conditions, with real-time tracking through the G-HUB, CELL TRACK and CELL PATH systems.
• Diagnostic Testing Service Clinical diagnostic testing and laboratory analysis services delivered through GC Labs to hospitals, clinics and clinical trial sponsors.
• Clinical Trial Sample Analysis (GCCL) Central-laboratory sample analysis and biomarker testing service supporting clinical trials for pharmaceutical and biotech sponsors.

Quantifiable outcome

• 37% reduction in recurrence risk and 79% reduction in mortality risk vs. active surveillance in Phase 3 HCC adjuvant trial (HR for RFS 0.63, HR for OS 0.21)
• +6 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eleven partnerships are on record, tiered minor, core and flagship.

• VisMederi S.r.l (Italy)minorStrategic or Co-development Partner · 3 April 2026GCCL (GC Cell's clinical trial sample analysis affiliate) and VisMederi, a European bioanalysis company, signed an MOU at World Vaccine Congress 2026 (WVC 2026) in Washington D.C. The partnership aims to leverage both companies' analytical expertise and regional networks to provide integrated clinical trial sample analysis services for vaccine development spanning Europe and Asia-Pacific. The companies plan to collaborate on high-risk pathogen vaccine candidate research, joint marketing, and project operations support.
• Samsung Medical CentercoreStrategic or Co-development Partner · 13 March 2025Samsung Medical Center serves as the lead investigative site for GC Cell's Phase 1 clinical trial of GCC2005 (CD5 CAR-NK) for relapsed or refractory NK and T-cell malignancies. Dr. Won Seog Kim of Samsung Medical Center is the lead investigator of the NCT06699771 trial enrolling approximately 48 patients.
• PT Bifarma Adiluhung (Bifarma)flagshipOEM/ Whitelabel/ Licensing Partner · 11 September 2024GC Cell executed a Technology Transfer and License Agreement with PT Bifarma Adiluhung, an Indonesian cell therapy company and subsidiary of PT Kalbe Farma (KALBE group), granting exclusive rights to develop, manufacture, and commercialize Immuncell-LC in Indonesia for 15 years. Bifarma operates Indonesia's first GMP-certified cell therapy production facility with a comprehensive oncology-focused sales infrastructure and cold chain distribution network. The partnership is aimed at introducing Immuncell-LC to Indonesia by 2025, targeting approximately 23,000 new HCC patients annually in the country.
• Artiva BiotherapeuticsflagshipStrategic or Co-development Partner · 11 September 2024GC Cell collaborates with Artiva Biotherapeutics on multiple NK cell therapy programs. GCC2005 (CD5 CAR-NK, AB-205) is being co-developed with Artiva for relapsed/refractory NK and T-cell malignancies. Artiva is developing GC Cell's NK cell therapy technology globally, with AB-101 (naive NK cell) in Phase 1 trials for lymphoma and lupus. Artiva operates from San Diego, CA, and was established in 2019 as a strategic vehicle for GC Cell's NK platform global expansion.
• Lukas Biomedical Co., Ltd. (Taiwan)flagshipStrategic or Co-development Partner · 22 July 2024GC Cell and Lukas Biomedical signed an international strategic cooperation agreement to expand autologous T cell therapy awareness and patient access in Taiwan and globally. Lukas licenses LuLym-T memory T cell cultivation technology from GC Lymphotec (a GC Group subsidiary). GC Cell and Lukas established a Joint Committee (JC) for clinical and commercial knowledge exchange, cross-licensing discussions, and joint clinical trials (IITs and SIT) in each other's regions. Lukas has agreements with 13 Taiwanese medical institutions including National Taiwan University Hospital and Chang Gung Memorial Hospital for Phase II clinical trials.
• Checkpoint TherapeuticscoreStrategic or Co-development Partner · 11 July 2024GC Cell and Checkpoint Therapeutics announced a collaboration to explore the combined therapeutic potential of cosibelimab (Checkpoint's anti-PD-L1 antibody with ADCC mechanism) with GC Cell's Immuncell-LC (autologous CIK T cell therapy). The collaboration focuses on in vitro combination studies to evaluate synergistic effects on cancer cell destruction, with potential for in vivo research and clinical studies. Both companies are exploring future commercial licensing or joint development opportunities.
• PT Kalbe Farma Tbk (KALBE group)coreChannel Partner/ Reseller/ Distributor · 19 June 2024Initial MOU signed between GC Cell and PT Bifarma Adiluhung (Bifarma), an affiliate of PT Kalbe Farma (KALBE group), Southeast Asia's leading pharmaceutical company. KALBE has 40+ subsidiaries, 14 international-standard production facilities, and ~16,000 employees across 71 branches in Indonesia. The MOU facilitated the eventual licensing agreement for Immuncell-LC commercialization in Indonesia.
• Made Scientific (USA)coreOEM/ Whitelabel/ Licensing Partner · 1 January 2022GC Cell acquired Made Scientific (established 2019, Newark, NJ, USA) in 2022. Made Scientific is a cell therapy CDMO with end-to-end clinical-to-commercial service capabilities, operating from two US-based manufacturing facilities. The acquisition expanded GC Cell's US manufacturing footprint and capabilities.
• GC Lymphotec (Japan)coreOEM/ Whitelabel/ Licensing Partner · 1 January 2016GC Cell acquired GC Lymphotec (established 1999, Tokyo, Japan) in 2016. GC Lymphotec holds global intellectual property rights and regenerative medicine-related licenses in Japan for activated autologous lymphocyte therapy (Sekine method) and licenses the LuLym-T memory T cell technology to Lukas Biomedical in Taiwan.
• GCCL (GC Cell Laboratory, Korea)coreTechnology or Integration · 1 January 2016GCCL was established in August 2016 as GC Cell's affiliate for global clinical central laboratory services. GCCL holds GCLP accreditation for all areas of clinical trial sample analysis and provides Phase I to Phase IV analytical services based on its own sample transportation logistics system.
• GC LabscoreTechnology or IntegrationGC Cell is linked with GC Labs, Korea's top clinical diagnostic institution, through its diagnostic testing and bio-logistics services. GC Labs has 75 branches nationwide with 400+ specialized specimen managers, conducting 5,000 test items and 100 million tests annually. GC Cell provides specimen transportation and logistics coordination while GC Labs performs the actual diagnostic testing.

Scale indicators13 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Fate Therapeutics: Clinical-stage company developing iPSC-derived NK and T cell therapies with off-the-shelf positioning. Comparable to GC Cell in allogeneic cell therapy modality and cord blood-derived / engineered NK cell platforms, though Fate uses iPSC rather than cord blood source material.
• Nkarta Therapeutics: Clinical-stage biopharmaceutical company developing allogeneic NK cell therapies for cancer and autoimmune disease. Directly comparable to GC Cell's AB-101 and CAR-NK pipeline in modality (allogeneic NK), target indications, and cryopreserved off-the-shelf positioning.
• Catalent: Major global CDMO offering cell therapy development and manufacturing services. Comparable to GC Cell's CDMO division in serving pharma and biotech clients across modalities, with deeper geographic reach and broader service portfolio.
• Adicet Bio: Clinical-stage company developing allogeneic gamma delta T cell and CAR-NK therapies for cancer and autoimmune disease. Comparable to GC Cell's allogeneic NK pipeline in modality, off-the-shelf cryopreserved positioning, and target indications including lymphoma and autoimmune disease.
• Samsung Biologics: Korean-headquartered biopharmaceutical CDMO with large-scale manufacturing capacity. Directly comparable as a regional CDMO competitor targeting global pharma clients; Samsung's scale and Samsung Group backing create both partnership and competitive overlap with GC Cell.
• Caribou Biosciences: Clinical-stage company developing allogeneic CAR-NK cell therapies using CRISPR-edited platform. Directly comparable to GC Cell's GCC2003/2004/2005 CAR-NK pipeline in modality, allogeneic positioning, and oncology target indications.
• Lonza Group: Global leader in cell and gene therapy CDMO services with manufacturing facilities across multiple continents. Directly comparable to GC Cell's CDMO division in offering autologous and allogeneic cell therapy manufacturing at commercial scale, though Lonza has broader modality coverage and deeper pharma relationships.

Regional players

• Celltrion: Korean biopharmaceutical leader in biosimilars with expanding cell and gene therapy investments. Comparable as a Korean-based biopharma expanding into advanced therapy modalities, though Celltrion's primary revenue remains in biosimilars.
• MEDIPOST: Korean stem cell therapy company with commercial cord blood-derived products and CDMO services. Comparable regional peer in Korean cell therapy market with similar stem cell modality focus and overlapping domestic hospital networks.

Broad incumbents

• Miltenyi Biotec: Privately held global provider of cell therapy manufacturing platforms, instruments, and CDMO services. Comparable to GC Cell across cell therapy manufacturing capability, though Miltenyi's portfolio spans instruments, reagents, and services as a broader life science tools incumbent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gccell

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Green Cross Lab Cell